Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Updated . What changed?
Foghorn Therapeutics Inc is a biotechnology business based in the US. Foghorn Therapeutics shares (FHTX) are listed on the NASDAQ and all prices are listed in US Dollars. Foghorn Therapeutics employs 85 staff and has a market cap (total outstanding shares value) of USD$629.1 million.
|Latest market close||USD$20.61|
|52-week range||USD$14.03 - USD$21.04|
|50-day moving average||USD$16.8926|
|200-day moving average||USD$16.8926|
|Wall St. target price||USD$25|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||N/A|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-12)||8.13%|
|1 month (2020-12-18)||-20.36%|
|3 months (2020-10-16)||N/A|
|6 months (2020-07-16)||N/A|
|1 year (2020-01-16)||N/A|
|2 years (2019-01-16)||N/A|
|3 years (2018-01-16)||N/A|
|5 years (2016-01-16)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||USD$629.1 million|
TTM: trailing 12 months
There are currently 19,697 Foghorn Therapeutics shares held short by investors – that's known as Foghorn Therapeutics's "short interest". This figure is 7.1% up from 18,396 last month.
There are a few different ways that this level of interest in shorting Foghorn Therapeutics shares can be evaluated.
Foghorn Therapeutics's "short interest ratio" (SIR) is the quantity of Foghorn Therapeutics shares currently shorted divided by the average quantity of Foghorn Therapeutics shares traded daily (recently around 393940). Foghorn Therapeutics's SIR currently stands at 0.05. In other words for every 100,000 Foghorn Therapeutics shares traded daily on the market, roughly 50 shares are currently held short.
To gain some more context, you can compare Foghorn Therapeutics's short interest ratio against those of similar companies.
However Foghorn Therapeutics's short interest can also be evaluated against the total number of Foghorn Therapeutics shares, or, against the total number of tradable Foghorn Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Foghorn Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Foghorn Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0011% of the tradable shares (for every 100,000 tradable Foghorn Therapeutics shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Foghorn Therapeutics.
Find out more about how you can short Foghorn Therapeutics stock.
We're not expecting Foghorn Therapeutics to pay a dividend over the next 12 months.
Foghorn Therapeutics Inc., a biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small-molecule enzymatic inhibitor of BRG1 and BRM for the treatment of acute myeloid leukemia and uveal melanoma; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing preclinical and discovery programs, including selective BRM targeting non-small-cell lung cancer; and selective ARID1B modulators for bladder, ovarian, and endometrial cancer. It has a collaboration with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Vacasa IPO, plus information on how to buy in.
Everything we know about the William Penn Bancorp IPO, plus information on how to buy in.
Everything we know about the Landos Biopharma Inc IPO, plus information on how to buy in.
Everything we know about the First High-School Education Group Co Ltd IPO, plus information on how to buy in.
Everything we know about the Knowlton Development Corp IPO, plus information on how to buy in.
Steps to owning and managing SASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAIL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SAF, with 24-hour and historical pricing before you buy.
Steps to owning and managing RDHL, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBFG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.